Effects of COVID-19 Infection and Vaccination in the Retina

Direct association and causation are still inconclusive.

By Fritz Gerald P. Kalaw, MD, William R. Freeman, MD

A 2023 Update on Treatment Paradigms and Options for Nonproliferative Diabetic Retinopathy

Future therapies could benefit more patients and include more durable options.

By Saagar A. Pandit, MD, MPH, Michael Klufas, MD

Neurotrophic Keratitis in Diabetic Patients Following Retinal Surgery

Maintain suspicion if postoperative dry eye symptoms do not resolve.

By Eric A. Lovett Jr., BS, MBA, Matthew R. Starr, MD, Ajay E. Kuriyan, MD, MS

Updates in the Diabetic Retinopathy Screening Landscape

Changes are on the horizon involving both teleretina and artificial intelligence.

By Ruby Hollinger, BA, Jayanth Sridhar, MD

The 2023 AAO Retina Product Pavilion

By Peter K. Kaiser, MD

The Diabetic Retinopathy Pipeline

Treatments are in trials from phase 1 to phase 3.

By Nathalie E. Perez, BS, Lauren C. Kiryakoza, MD, Jayanth Sridhar, MD

Clinical Pearls for Newly Approved Treatments for GA

The landscape for geographic atrophy (GA) secondary to AMD is experiencing its largest shift ever with 2 treatment agents that recently received FDA approval.

By Aamir A. Aziz, BS, Carl Danzig, MD

UPFRONT: The Global Burden of Diabetes

By Peter K. Kaiser, MD

CLINICAL TRIAL DOWNLOAD: Twelve-month Data From a Phase 1 Clinical Trial of OTX-TKI for Wet AMD

Drug delivery could be extended for months.

By Arshad M. Khanani, MD, MA, FASRS, Paula Pecen, MD, Rabia Gurses Ozden, MD

CODING Q&A: Billing Pediatric Retina Cases

Many factors must be considered when coding and billing retinopathy of prematurity cases.

By Matthew Baugh, MHA, COT, OCS, OCSR

UVEITIS CORNER: Medication Adherence and Patient Education in Management of Chronic Uveitis

Comprehensive educational resources are critical to good outcomes.

By Arthi D. Bharadwaj, BS, Ann-Marie Lobo-Chan, MD, MS

NEW PRODUCT APPLICATIONS: Optos Retinal Imaging System Offers New Color Modality

Additional data help physicians make more informed decisions.

By Karen Appold, contributing writer

Clinical Trial Update October 2023

SUBSPECIALTY NEWS: Biosimilar FDA application hits roadblock, Apellis provides guidance on Syfovre use, and more.

By Rochelle Nataloni, contributing writer